Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Colistin Methanesulfonate Is Efficacious and Safe for the Management of Sepsis in Hematological Diseases Patients: A Retrospective Study in China

Yan Xie, Ziyi Liu, Peiqi Liang, Depei Wu, Jianhong Fu

Blood (2024) 144 (Supplement 1): 5992.

https://doi.org/10.1182/blood-2024-204894

Published: 2024

Journal Articles

Prognosis Prediction and Treatment Recommendation for Follicular Lymphoma: Enhancing Decision-Making

Xinze Li, Jiaxin Liu, Lan Mi, Liantao Ma, Junyi Gao, Yan Xie, Yuqin Song

Blood (2024) 144 (Supplement 1): 6353.

https://doi.org/10.1182/blood-2024-212407

Published: 2024

Journal Articles

Time Series Deep Neural Network Identifies Lymphoma Patients Suitable for CAR-T Cell Therapy Using EHR Data

Meihua Long, Fan Jia, Jili Deng, Jianing Zhang, Ziran Zhao, Yan Xie, Lan Mi, Yan Hou, Yuqin Song

Blood (2024) 144 (Supplement 1): 2233.

https://doi.org/10.1182/blood-2024-209699

Published: 2024

Journal Articles

Anti-Btla Antibody Tifcemalimab As a Single Agent or in Combination with Toripalimab in Relapsed/Refractory Lymphomas

Blood (2023) 142 (Supplement 1): 4458.

https://doi.org/10.1182/blood-2023-181385

Published: 2023

Journal Articles

GB261, an Fc-Function Enabled and CD3 Affinity De-Tuned CD20/CD3 Bispecific Antibody, Demonstrated a Highly Advantageous Safety/Efficacy Balance in an Ongoing First-in-Human Dose-Escalation Study in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

Yuqin Song, Zengjun Li, Ling Li, Zhengzi Qian, Keshu Zhou, Lei Fan, Peter Tan, Pratyush Giri, Zhiming Li, Melita Kenealy, Jie Jin, Wei Liu, Shafqat Inam, Yan Xie, Xia Guo, Wenduo He, Raymond Xu, Tong Li, Jun Zhu

Blood (2023) 142 (Supplement 1): 1719.

https://doi.org/10.1182/blood-2023-188444

Published: 2023

Journal Articles

Dynamic Single-Cell Profiling Reveals Novel Immune Regulatory Mechanism of ITK Inhibitor Soquelitinib in Refractory T Cell Lymphoma

Ning Ding, Yan Xie, Yong Guo, Kecheng Li, Tingting DU, Zhenjun Li, Yuejiao Li, Jiaowu Cao, Dingyao Hu, Lih-Yun Hsu, Richard Miller, Jun Zhu, Yuqin Song

Blood (2023) 142 (Supplement 1): 1442.

https://doi.org/10.1182/blood-2023-174421

Published: 2023

Journal Articles

Venetoclax Combined with Hypomethylating Agents in Acute Myeloid Leukemia Patients Serious Complications Admitted to a Special Hematological Intensive Care Unit

Peiqi Liang, Depei Wu, Yan Xie, Ziyi Liu, Jianhong Fu

Blood (2023) 142 (Supplement 1): 5944.

https://doi.org/10.1182/blood-2023-173088

Published: 2023

Journal Articles

Phase I Study of the Anti-Btla Antibody Tifcemalimab As a Single Agent or in Combination with Toripalimab in Relapsed/Refractory Lymphomas

Jun Ma, Yuqin Song, Yan Xie, Hui-Lai Zhang, Yuerong Shuang, Zhigang Peng, Li Fei, Yunhong Huang, Weili Zhao, Wenrong Huang, Yali Pan, Mingying Liu, Feiwu Ran, Hui Feng, Sheng Yao, Patricia Keegan, Jianjun Zou, Jun Zhu

Blood (2022) 140 (Supplement 1): 3716–3717.

https://doi.org/10.1182/blood-2022-157497

Published: 2022

Journal Articles

Targeting 1q21 Amplification with APG2575 and Lenalidomide to Sensitize BCL-2 Inhibition with the Decrease of MCL-1 Protein in High Risk MM Models

Yan Xie, MD, Chengcheng FU, MD PhD, Lingzhi Yan, MD PhD, Song Jin, MD, Jingjing Shang, MD, Xiaolan Shi, MD PhD, Jinlan Pan, MD, Yan Yin, MS, Tingting Mao, MS, Jing Deng, PhD, Douglas D. Fang, MD PhD, Dajun Yang, MD PhD, Yifan Zhai, MD PhD, Shuang Yan, MD, Yingying Zhai, MD, Ying Yao, MD, Panfeng Wang, MD, Jing Wang, MD, Depei Wu, MDPhD

Blood (2020) 136 (Supplement 1): 46–47.

https://doi.org/10.1182/blood-2020-139195

Published: 2020

Journal Articles

CD19 CAR T Cell Product Exhibits High Remission Rate in Adult Relapsed and/or Refractory B-Cell Non-Hodgkin Lymphoma

Zhitao Ying, MD PhD, Wen Wang, MD, Xiaopei Wang, MD, Wen Zheng, MD, Ningjing Lin, MD PhD, Meifeng Tu, MD PhD, Yan Xie, MD PhD, Lingyan Ping, MD PhD, Chen Zhang, MD PhD, Weiping Liu, MD PhD, Lijuan Deng, MD PhD, Ming Hao, Su Yang, Yan Zhou, BSc, James Li, Yuqin Song, MD PhD, Jun Zhu, MD PhD

Blood (2018) 132 (Supplement 1): 5388.

https://doi.org/10.1182/blood-2018-99-114527

Published: 2018

Journal Articles

Incidence, Clinical Characteristics and Outcome of Cardiac Toxicity in Elderly Patients with Diffuse Large B-Cell Lymphoma

Wei Ping Liu, Yan Feng Xu, Yan Xie, Xiaopei Wang, MD, Yuqin Song, MD PhD, Jun Zhu, MD PhD

Blood (2018) 132 (Supplement 1): 5416.

https://doi.org/10.1182/blood-2018-99-117955

Published: 2018

Journal Articles

The Intracellular TCR Signaling Pathway As a Novel Therapeutic Target in AITL Patients

Yalu Liu, Ning Ding, MD, Xiaogan Wang, MD, Lijuan Deng, MD, Lingyan Ping, Yunfei Shi, Wen Zheng, Ningjing Lin, Xiaopei Wang, Meifeng Tu, Yan Xie, Weiping Liu, Zhitao Ying, Chen Zhang, Zhengying Pan, Xi Wang, Yuqin Song, MD, Jun Zhu, BS

Blood (2017) 130 (Supplement 1): 1461.

https://doi.org/10.1182/blood.V130.Suppl_1.1461.1461

Published: 2017

Journal Articles

Efficacy of Lower Dose Rituximab by Adding Fresh Frozen Plasma for the Treatment of Idiopathic Thrombocytopenic Purpura

Mei Sun, JIan Gu, Bin He, Xiao-Yan Xie, Bao-An Chen, MD, PhD, Xiao-Ping Pei

Blood (2010) 116 (21): 4682.

https://doi.org/10.1182/blood.V116.21.4682.4682

Published: 2010

Journal Articles

STAT5 requires the N-domain for suppression of miR15/16, induction of bcl-2, and survival signaling in myeloproliferative disease

Geqiang Li, Kristy L. Miskimen, Zhengqi Wang, Xiu Yan Xie, Jennifer Brenzovich, John J. Ryan, William Tse, Richard Moriggl, Kevin D. Bunting

Blood (2010) 115 (7): 1416–1424.

https://doi.org/10.1182/blood-2009-07-234963

Published: 2010

Includes: Supplemental data

Journal Articles

Genetic and Pharmacologic Targeting of STAT5/Gab2/PI3K/mTOR Signaling in a Mouse Myeloproliferative Disease Model.

Geqiang Li, Ph.D., Zhengqi Wang, Ph.D., Kristy L. Miskimen, Ph.D., Xiu Yan Xie, M.D., William Tse, M.D., Fabrice Gouilleux, Ph.D., Richard Moriggl, Ph.D., Kevin D. Bunting, Ph.D.

Blood (2009) 114 (22): 3902.

https://doi.org/10.1182/blood.V114.22.3902.3902

Published: 2009

Journal Articles

STAT5 Requires the N-Domain for Suppression of miR15/16, Induction of Bcl-2, and Survival Signaling in Myeloproliferative Disease.

Geqiang Li, Ph.D., Kristy L. Miskimen, Ph.D., Zhengqi Wang, Ph.D., Xiu Yan Xie, M.D., Jennifer Brenzovich, B.S., John J Ryan, Ph.D., William Tse, M.D., Richard Moriggl, Ph.D., Kevin D. Bunting, Ph.D.

Blood (2009) 114 (22): 211.

https://doi.org/10.1182/blood.V114.22.211.211

Published: 2009

Journal Articles

Cytoplasmic localization of phosphorylated STAT5 in human acute myeloid leukemia is inversely correlated with Flt3-ITD

Kevin D. Bunting, Xiu Yan Xie, Ilka Warshawsky, Eric D. Hsi

Blood (2007) 110 (7): 2775–2776.

https://doi.org/10.1182/blood-2007-05-090969

Published: 2007

Journal Articles

Delineation of a minimal interval and identification of 9 candidates for a tumor suppressor gene in malignant myeloid disorders on 5q31

Stephen K. Horrigan, Zarema H. Arbieva, Hong Yan Xie, Jelena Kravarusic, Noreen C. Fulton, Haley Naik, Tiffany T. Le, Carol A. Westbrook

Blood (2000) 95 (7): 2372–2377.

https://doi.org/10.1182/blood.V95.7.2372

Published: 2000

NARROW

Colistin Methanesulfonate Is Efficacious and Safe for the Management of Sepsis in Hematological Diseases Patients: A Retrospective Study in China

Prognosis Prediction and Treatment Recommendation for Follicular Lymphoma: Enhancing Decision-Making

Time Series Deep Neural Network Identifies Lymphoma Patients Suitable for CAR-T Cell Therapy Using EHR Data

Anti-Btla Antibody Tifcemalimab As a Single Agent or in Combination with Toripalimab in Relapsed/Refractory Lymphomas

GB261, an Fc-Function Enabled and CD3 Affinity De-Tuned CD20/CD3 Bispecific Antibody, Demonstrated a Highly Advantageous Safety/Efficacy Balance in an Ongoing First-in-Human Dose-Escalation Study in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

Dynamic Single-Cell Profiling Reveals Novel Immune Regulatory Mechanism of ITK Inhibitor Soquelitinib in Refractory T Cell Lymphoma

Venetoclax Combined with Hypomethylating Agents in Acute Myeloid Leukemia Patients Serious Complications Admitted to a Special Hematological Intensive Care Unit

Phase I Study of the Anti-Btla Antibody Tifcemalimab As a Single Agent or in Combination with Toripalimab in Relapsed/Refractory Lymphomas

Targeting 1q21 Amplification with APG2575 and Lenalidomide to Sensitize BCL-2 Inhibition with the Decrease of MCL-1 Protein in High Risk MM Models

CD19 CAR T Cell Product Exhibits High Remission Rate in Adult Relapsed and/or Refractory B-Cell Non-Hodgkin Lymphoma

Incidence, Clinical Characteristics and Outcome of Cardiac Toxicity in Elderly Patients with Diffuse Large B-Cell Lymphoma

The Intracellular TCR Signaling Pathway As a Novel Therapeutic Target in AITL Patients

Efficacy of Lower Dose Rituximab by Adding Fresh Frozen Plasma for the Treatment of Idiopathic Thrombocytopenic Purpura

STAT5 requires the N-domain for suppression of miR15/16, induction of bcl-2, and survival signaling in myeloproliferative disease

Genetic and Pharmacologic Targeting of STAT5/Gab2/PI3K/mTOR Signaling in a Mouse Myeloproliferative Disease Model.

STAT5 Requires the N-Domain for Suppression of miR15/16, Induction of Bcl-2, and Survival Signaling in Myeloproliferative Disease.

Cytoplasmic localization of phosphorylated STAT5 in human acute myeloid leukemia is inversely correlated with Flt3-ITD

Delineation of a minimal interval and identification of 9 candidates for a tumor suppressor gene in malignant myeloid disorders on 5q31

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only